Clinical trials: RSV
RSV
Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.
- Trial name
- NCT05096208
- Testing
- RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3)
- Where
- 18 sites in United States
- Volunteers
- 1,028 people, healthy volunteers welcome
- Sponsor
- Pfizer